Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer

Chung-Huei Hsu, Ren Shyan Liu, Chih-Hsiung Wu, Su Mei Chen, Li Sun Shih

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background and Purpose: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a relatively new modality in the follow-up of patients with differentiated thyroid cancer (DTC) who have undergone total thyroidectomy and postoperative radioiodine therapy. The aim of this study was to assess the diagnostic value of FDG-PET, comparing it with 131I whole-body scan (WBS) and 201T1 WBS. Methods: Fifteen selected patients with local invasive and/or aggressive DTC were included in this study. The follow-up period ranged from 1 to 12 years, with a mean ± standard error of 6 ± 3 years. FDG-PET was performed when patients were still receiving thyroxin therapy. Results: In the cervical region, residual cancer in two patients was demonstrated by FDG-PET, but could not be detected using 131I WBS or 201T1 WBS. Pathology of the surgical specimen showed dedifferentiation of thyroid cancer in one of these patients. Metastatic cervical lymph nodes were detected using FDG-PET in three patients, but in only one patient using 131I WBS and in another one patient using 201T1 WBS. Mediastinal metastases were detected using FDG-PET in three patients, 131I WBS in two patients, and 201T1 WBS in one patient. Diffuse lung metastasis was detected only by 131I WBS in two patients. The use of FDG-PET in conjunction with computerized tomography provided useful diagnostic information about small nodular lesions of the lung which could not be localized by 131I WBS or 201T1 WBS in three patients. In skeletal metastases, 131I WBS detected more metastatic lesions than FDG-PET or 201T1 WBS, especially when the lesions were located in the pelvis. Conclusions: In the follow-up evaluation of patients with post-therapy DTC, FDG-PET was useful for detecting dedifferentiated lesions and was superior to 131I WBS in detecting residual cervical or mediastinal lesions and suspected small metastatic foci in the lung. FDG-PET was inferior to 131I WBS in detecting diffuse lung metastases and distant bone metastases.

Original languageEnglish
Pages (from-to)459-467
Number of pages9
JournalJournal of the Formosan Medical Association = Taiwan yi zhi
Volume101
Issue number7
Publication statusPublished - Jul 2002

Fingerprint

Whole Body Imaging
Fluorodeoxyglucose F18
Thyroid Neoplasms
Positron-Emission Tomography
Therapeutics
Neoplasm Metastasis
Lung
Surgical Pathology
Thyroidectomy
Residual Neoplasm
Pelvis
Thyroxine

Keywords

  • I
  • T1
  • Dedifferentiation
  • FDG-PET
  • Thyroid cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer. / Hsu, Chung-Huei; Liu, Ren Shyan; Wu, Chih-Hsiung; Chen, Su Mei; Shih, Li Sun.

In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 101, No. 7, 07.2002, p. 459-467.

Research output: Contribution to journalArticle

@article{9fc16d3bcbae440a9bda60362e955197,
title = "Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer",
abstract = "Background and Purpose: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a relatively new modality in the follow-up of patients with differentiated thyroid cancer (DTC) who have undergone total thyroidectomy and postoperative radioiodine therapy. The aim of this study was to assess the diagnostic value of FDG-PET, comparing it with 131I whole-body scan (WBS) and 201T1 WBS. Methods: Fifteen selected patients with local invasive and/or aggressive DTC were included in this study. The follow-up period ranged from 1 to 12 years, with a mean ± standard error of 6 ± 3 years. FDG-PET was performed when patients were still receiving thyroxin therapy. Results: In the cervical region, residual cancer in two patients was demonstrated by FDG-PET, but could not be detected using 131I WBS or 201T1 WBS. Pathology of the surgical specimen showed dedifferentiation of thyroid cancer in one of these patients. Metastatic cervical lymph nodes were detected using FDG-PET in three patients, but in only one patient using 131I WBS and in another one patient using 201T1 WBS. Mediastinal metastases were detected using FDG-PET in three patients, 131I WBS in two patients, and 201T1 WBS in one patient. Diffuse lung metastasis was detected only by 131I WBS in two patients. The use of FDG-PET in conjunction with computerized tomography provided useful diagnostic information about small nodular lesions of the lung which could not be localized by 131I WBS or 201T1 WBS in three patients. In skeletal metastases, 131I WBS detected more metastatic lesions than FDG-PET or 201T1 WBS, especially when the lesions were located in the pelvis. Conclusions: In the follow-up evaluation of patients with post-therapy DTC, FDG-PET was useful for detecting dedifferentiated lesions and was superior to 131I WBS in detecting residual cervical or mediastinal lesions and suspected small metastatic foci in the lung. FDG-PET was inferior to 131I WBS in detecting diffuse lung metastases and distant bone metastases.",
keywords = "I, T1, Dedifferentiation, FDG-PET, Thyroid cancer",
author = "Chung-Huei Hsu and Liu, {Ren Shyan} and Chih-Hsiung Wu and Chen, {Su Mei} and Shih, {Li Sun}",
year = "2002",
month = "7",
language = "English",
volume = "101",
pages = "459--467",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer

AU - Hsu, Chung-Huei

AU - Liu, Ren Shyan

AU - Wu, Chih-Hsiung

AU - Chen, Su Mei

AU - Shih, Li Sun

PY - 2002/7

Y1 - 2002/7

N2 - Background and Purpose: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a relatively new modality in the follow-up of patients with differentiated thyroid cancer (DTC) who have undergone total thyroidectomy and postoperative radioiodine therapy. The aim of this study was to assess the diagnostic value of FDG-PET, comparing it with 131I whole-body scan (WBS) and 201T1 WBS. Methods: Fifteen selected patients with local invasive and/or aggressive DTC were included in this study. The follow-up period ranged from 1 to 12 years, with a mean ± standard error of 6 ± 3 years. FDG-PET was performed when patients were still receiving thyroxin therapy. Results: In the cervical region, residual cancer in two patients was demonstrated by FDG-PET, but could not be detected using 131I WBS or 201T1 WBS. Pathology of the surgical specimen showed dedifferentiation of thyroid cancer in one of these patients. Metastatic cervical lymph nodes were detected using FDG-PET in three patients, but in only one patient using 131I WBS and in another one patient using 201T1 WBS. Mediastinal metastases were detected using FDG-PET in three patients, 131I WBS in two patients, and 201T1 WBS in one patient. Diffuse lung metastasis was detected only by 131I WBS in two patients. The use of FDG-PET in conjunction with computerized tomography provided useful diagnostic information about small nodular lesions of the lung which could not be localized by 131I WBS or 201T1 WBS in three patients. In skeletal metastases, 131I WBS detected more metastatic lesions than FDG-PET or 201T1 WBS, especially when the lesions were located in the pelvis. Conclusions: In the follow-up evaluation of patients with post-therapy DTC, FDG-PET was useful for detecting dedifferentiated lesions and was superior to 131I WBS in detecting residual cervical or mediastinal lesions and suspected small metastatic foci in the lung. FDG-PET was inferior to 131I WBS in detecting diffuse lung metastases and distant bone metastases.

AB - Background and Purpose: 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a relatively new modality in the follow-up of patients with differentiated thyroid cancer (DTC) who have undergone total thyroidectomy and postoperative radioiodine therapy. The aim of this study was to assess the diagnostic value of FDG-PET, comparing it with 131I whole-body scan (WBS) and 201T1 WBS. Methods: Fifteen selected patients with local invasive and/or aggressive DTC were included in this study. The follow-up period ranged from 1 to 12 years, with a mean ± standard error of 6 ± 3 years. FDG-PET was performed when patients were still receiving thyroxin therapy. Results: In the cervical region, residual cancer in two patients was demonstrated by FDG-PET, but could not be detected using 131I WBS or 201T1 WBS. Pathology of the surgical specimen showed dedifferentiation of thyroid cancer in one of these patients. Metastatic cervical lymph nodes were detected using FDG-PET in three patients, but in only one patient using 131I WBS and in another one patient using 201T1 WBS. Mediastinal metastases were detected using FDG-PET in three patients, 131I WBS in two patients, and 201T1 WBS in one patient. Diffuse lung metastasis was detected only by 131I WBS in two patients. The use of FDG-PET in conjunction with computerized tomography provided useful diagnostic information about small nodular lesions of the lung which could not be localized by 131I WBS or 201T1 WBS in three patients. In skeletal metastases, 131I WBS detected more metastatic lesions than FDG-PET or 201T1 WBS, especially when the lesions were located in the pelvis. Conclusions: In the follow-up evaluation of patients with post-therapy DTC, FDG-PET was useful for detecting dedifferentiated lesions and was superior to 131I WBS in detecting residual cervical or mediastinal lesions and suspected small metastatic foci in the lung. FDG-PET was inferior to 131I WBS in detecting diffuse lung metastases and distant bone metastases.

KW - I

KW - T1

KW - Dedifferentiation

KW - FDG-PET

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=0036629529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036629529&partnerID=8YFLogxK

M3 - Article

C2 - 12353337

AN - SCOPUS:0036629529

VL - 101

SP - 459

EP - 467

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 7

ER -